EGFR and neoplasm: Conversely, amongst the 158-overexpressed tumor genes, there were 8 targets with inhibitors either commercially available or in clinical trials, including EGFR/cetuximab-prochlorperazine (Fig. 2i)21 and 9 experimental targets supported by preclinical data (Fig. 2j, Supplementary Table 4)22.